期刊文献+

高密度脂蛋白胆固醇与动脉粥样硬化研究进展 被引量:6

下载PDF
导出
摘要 低密度脂蛋白胆固醇(LDL—C)一直占据着动脉粥样硬化性疾病(atherosclerosis,AS)防治研究的主导地位,降低血浆LDL-C水平一直是防治AS的目标,然而即使LDL—C已降至血脂防治指南目标值以下,仍有2/3患者发生冠心病。大量临床及流行病学研究证实,As与高密度脂蛋白胆固醇(HDL—C)血浆水平成负相关,低HDL—C血症是AS的独立预测因素。
作者 王晓娜 叶平
出处 《中华保健医学杂志》 2015年第6期516-517,520,共3页 Chinese Journal of Health Care and Medicine
基金 国家自然基金(8127090941)
  • 相关文献

参考文献16

  • 1汤涌,黄进,陆治平,杨明智.冠心病患者高密度脂蛋白胆固醇状况分析[J].实用全科医学,2006,4(4):386-387. 被引量:28
  • 2Subedi BH,Joshi PH,Jones SR,et al. Current guidelines for high-density lipoprotein cholesterol in therapy and future directions[J].Vasc Health Risk Manag,2014, 8(10) :205-216.
  • 3ACCORD Study Group, et al. Effects of combination lipid therapy in type 2 diabetes mellitus [J~. N Engl J Med,2010,362 (7): 1563-1574.
  • 4HPS2-THRIVE Collaborative Group. HPS2-TtIRIVE randomized placebo controlled trial in 25673 high-risk patients of ER niacin/ laropiprant: trial design, prespecified muscle and livm, outcomes,and reasons for stopping study treatment [J]. Eur Heart J,2013,34 (17) : 1279-1291.
  • 5Babrami H,Bluemke DA,Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atheroselerosis) study[Jl. J Am CoU Cardiol,2008,6 ;51 (18) : 1775-1783.
  • 6Zhao Y, Black AS, Bonnet DJ, et al. In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-IIJ]. J Lipid Res,2014,55(10):2053- 2063.
  • 7Krauss RM,Wojnooski K,Orr J,et al. Changes in lipoprotein subfraetion eonee-ntration and composition in healthy individuals treated with the CETP inhibitor anaeetrapib[J]. J Lipid Res, 2012,53(3) :540-547.
  • 8Zago VHD, Tanus-Santos JE, Danelon MRG, et al. Chemical modification of high density lipoprotein subfraetions-HDL2 and HDL3-after use of atorvastatin [J]. Int J Clin Pharmaeol Ther, 2014,52 (4) :277- 283.
  • 9Najafi-Shoushtari SH,Kristo F,Li Y, et al. MieroRNA-33 and the SREBP host genes cooperate to control eholesterolhomeostasis. Seienee[Jl.2010,18,328 (59 85) : 1566-1569.
  • 10Rayner KJ,Sheedy FJ,Esan CC,et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport andregression of atheroselerosis [ J ]. J Clin Invest, 2011,121 ( 7 ) : 2921-2931.

二级参考文献3

共引文献27

同被引文献47

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部